Thursday 14th September 2023 |
Text too small? |
Cannasouth Limited (NZX: CBD ) has exported to Australia its first commercial shipment of its high-purity cannabidiol (CBD) isolate, a cannabis-based, active pharmaceutical ingredient (API). This is a first for Aotearoa New Zealand’s medicinal cannabis industry.
This CBD isolate was manufactured in New Zealand to PIC/s Good Manufacturing Practice (GMP) standards and verified by the Medicinal Cannabis Agency. This first shipment is the forerunner of greater volumes of API exports for the local industry, signalling the demand for high-quality, GMP certified cannabis-based APIs on the international stage.
This signals the next growth phase for Cannasouth and the medicinal cannabis industry.
-ENDS-
No comments yet
Me Today - Notice of Annual Shareholder Meeting
FSF - Director Scott St John to retire from Fonterra Board
Greenfern announces change in Chief Financial Officer
AIA Provision of Financial Assistance - Employee Share Plan
CBD - Recording and Presentation of Investor Call
AUCKLAND CAR PARK CONCESSION AGREEMENT - HIGH COURT JUDGMENT
CRP - Korella North Mining Lease Lodgement Approved
Genesis Energy launches new strategy
November 30th Morning Report
IFT270 - Interest Rate Reset